Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timed versus untimed VCML vaccine in advanced melanoma
ACTRN12612001069842Phase 2Terminated
- Sponsor
- Australian Melanoma Research Foundation
- Start
- Apr 2014
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vaccinia melanoma cell lysate vaccine and cyclophosphamide in melanoma (2 arms), sponsored by Australian Melanoma Research Foundation. Primary endpoints: Complete response rate and Overall survival. Started Apr 2014; status: terminated.
02
Drugs
vaccinia melanoma cell lysate vaccinecyclophosphamide
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12612001069842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001069842.